4.7 Article

Intestinal adenoma formation and MYC activation are regulated by cooperation between MYB and Wnt signaling

Journal

CELL DEATH AND DIFFERENTIATION
Volume 16, Issue 11, Pages 1530-1538

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/cdd.2009.94

Keywords

beta-catenin; MYB; MYC; colon cancer; APC; min mice

Funding

  1. NHMRC, Australia
  2. Microbiology and Department of Molecular Genetics
  3. University of California, Irvine, CA, USA

Ask authors/readers for more resources

Aberrant Wnt signaling mediated by mutations affecting APC ( adenomatous polyposis coli) or beta-catenin initiates the majority of human colorectal cancers (CRC) and drives tumorigenesis through the activation of specific genes such as MYC. We report here a novel association whereby another oncogenic transcription factor, MYB/c-Myb, is necessary for intestinal adenoma development directed by activated Wnt signaling. APC(Min/+) mice in which c-myb is haploinsufficient survive longer than wildtype APC(Min/+) animals due to a delay in adenoma formation. Intestinal adenomas from APC(Min/+) mice were assessed and found to have high levels of c-myc gene expression. We explored the relationship between activated Wnt signaling and MYB in regulating MYC and found activated beta-catenin in combination with MYB induces robust upregulation of MYC promoter activity, as well as endogenous MYC mRNA and protein expression, in human cells. This cooperation occurred through independent binding of MYB and beta-catenin to the MYC promoter. These data highlight a cooperative function for MYB in the context of activated Wnt signaling and provide a molecular basis for the expression of MYC in CRC. Cell Death and Differentiation (2009) 16, 1530-1538; doi:10.1038/cdd.2009.94; published online 17 July 2009

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Oncology

ASO Author Reflections: Organoid-Based Precision Medicine in Colorectal Cancer-Are We There Yet?

Michael Flood, Robert Ramsay, Alexander Heriot

ANNALS OF SURGICAL ONCOLOGY (2022)

Article Multidisciplinary Sciences

Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia

Mahmoud A. Bassal, Saumya E. Samaraweera, Kelly Lim, Brooks A. Bernard, Sheree Bailey, Satinder Kaur, Paul Leo, John Toubia, Chloe Thompson-Peach, Tran Nguyen, Kyaw Ze Ya Maung, Debora A. Casolari, Diana G. Iarossi, Ilaria S. Pagani, Jason Powell, Stuart Pitson, Siria Natera, Ute Roessner, Ian D. Lewis, Anna L. Brown, Daniel G. Tenen, Nirmal Robinson, David M. Ross, Ravindra Majeti, Thomas J. Gonda, Daniel Thomas, Richard J. D'Andrea

Summary: This study reveals the mutual exclusivity between germline mutations in mitochondrial complex I and somatic mutations in the metabolic enzyme IDH1 in patients with acute myeloid leukemia (AML), and finds that IDH1 mutant cells have increased sensitivity to complex I inhibitors.

NATURE COMMUNICATIONS (2022)

Article Oncology

A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary

Atara Posner, Owen Wj Prall, Tharani Sivakumaran, Dariush Etemadamoghadam, Niko Thio, Andrew Pattison, Shiva Balachander, Krista Fisher, Samantha Webb, Colin Wood, Anna DeFazio, Nicholas Wilcken, Bo Gao, Christos S. Karapetis, Madhu Singh, Ian M. Collins, Gary Richardson, Christopher Steer, Mark Warren, Narayan Karanth, Gavin Wright, Scott Williams, Joshy George, Rodney J. Hicks, Alex Boussioutas, Anthony J. Gill, Benjamin J. Solomon, Huiling Xu, Andrew Fellowes, Stephen B. Fox, Penelope Schofield, David Bowtell, Linda Mileshkin, Richard W. Tothill

Summary: This study compared the diagnostic utility of RNA and DNA tests in 215 CUP patients, and found that DNA mutation profiling was more diagnostically informative, especially for cases unresolved by clinicopathology assessment alone.

JOURNAL OF PATHOLOGY (2023)

Article Cell Biology

Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells

Dylan Jones, Clarissa A. Whitehead, Marija Dinevska, Samuel S. Widodo, Liam M. Furst, Andrew P. Morokoff, Andrew H. Kaye, Katharine J. Drummond, Theo Mantamadiotis, Stanley S. Stylli

Summary: Glioblastoma is a highly invasive and destructive brain tumor, and current standard treatments often fail to effectively eliminate it. In this study, we investigate the effects of several FDA-approved drugs on the invasion and viability of GBM cells. We found that these drugs can reduce cell invasion and viability, suggesting their potential as therapeutic options for GBM.

MOLECULAR AND CELLULAR BIOCHEMISTRY (2023)

Article Economics

Healthcare Costs Before and After Diagnosis of Cancer of Unknown Primary Versus Ovarian Cancer in Australia

Louisa G. Gordon, C. Wood, R. W. Tothill, P. M. Webb, P. Schofield, L. Mileshkin

Summary: This study aimed to describe and quantify healthcare resource usage and costs for patients with cancer of unknown primary (CUP) in Australia, and compare them with patients with ovarian cancer. The study found that pre-diagnosis costs for CUP patients were nearly triple those for ovarian cancer patients. Six months after diagnosis, healthcare costs remained higher for CUP patients than for ovarian cancer patients.

PHARMACOECONOMICS-OPEN (2023)

Article Oncology

A qualitative study of patients with Cancer of Unknown Primary: Perceptions of communication, understanding of diagnosis and genomic testing, and information needs

Kamil Wolyniec, Clare O'Callaghan, Krista Fisher, Sharp Jessica, Richard W. W. Tothill, David Bowtell, Mileshkin Linda, Penelope Schofield

Summary: Patients with Cancer of Unknown Primary (CUP) often have poor understanding of their illness and high levels of psychological distress. This study aimed to understand patients' experiences of communication with doctors, their understanding of diagnosis, and the role of genomic testing, as well as their information needs. Semi-structured interviews were conducted with CUP patients, and qualitative analysis was performed. Results showed varied perceptions of communication, different levels of information needs, and limited understanding of genomic testing among patients.

PSYCHO-ONCOLOGY (2023)

Article Oncology

Cell signaling activation and extracellular matrix remodeling underpin glioma tumor microenvironment heterogeneity and organization

Marija Dinevska, Samuel S. Widodo, Liam Furst, Lucero Cuzcano, Yitong Fang, Stefano Mangiola, Paul J. Neeson, Phillip K. Darcy, Robert G. Ramsay, Ryan Hutchinson, Fabienne MacKay, Michael Christie, Stanley S. Stylli, Theo Mantamadiotis

Summary: Tumor microenvironment in malignant astrocytoma undergoes changes in cell composition, cell signaling activation, and extracellular matrix deposition during disease progression. Targeting the extracellular matrix and cell signaling activation will be critical in designing personalized therapy.

CELLULAR ONCOLOGY (2023)

Review Oncology

Advances in CAR T cell immunotherapy for paediatric brain tumours

Padmashree Rao, Liam Furst, Deborah Meyran, Chelsea Mayoh, Paul J. Neeson, Rachael Terry, Dong-Anh Khuong-Quang, Theo Mantamadiotis, Paul G. Ekert

Summary: Pediatric brain tumors are the most common solid tumor in children, and current treatments include surgery, chemotherapy, and radiotherapy. Immunotherapy, especially CAR T cell therapy, may provide new avenues for improved outcomes.

FRONTIERS IN ONCOLOGY (2022)

Editorial Material Hematology

MYB deficiency leads to myeloid neoplasia too

Thomas J. Gonda

Summary: Clarke et al(1) demonstrate in this study that loss of 1 allele of Myb in mice leads to increased myeloproliferation and development of myeloid neoplasms, including AML, during aging. This is surprising given the established role of MYB in normal hematopoiesis and leukemogenesis. These findings suggest that even partial loss of MYB activity can predispose individuals to myeloid neoplasms.

BLOOD (2023)

Article Oncology

Somatic mutation landscape in a cohort of meningiomas that have undergone grade progression

Sarah A. Cain, Bernard Pope, Stefano Mangiola, Theo Mantamadiotis, Katharine J. Drummond

Summary: This study aimed to identify somatic mutations and copy number alterations associated with grade progression in meningiomas. Through targeted next-generation sequencing, mutations and CNAs associated with different grade progression were found. NF2 mutations played an important role in grade progression.

BMC CANCER (2023)

Review Cell Biology

Technological advances define shifting pathway signaling from normal to primary and metastatic colorectal cancer

Robert G. Ramsay, Vicki Whitehall, Michael P. Flood

Summary: Adoption of organoid/tumoroid propagation of normal and malignant intestinal epithelia has provided unprecedented opportunities to compare cell growth factor and signaling dependencies. These 3D structures mimic tumors in terms of gene expression and offer deeper insights into the tumor microenvironment (TME). Manipulation of TME elements and evaluation of different therapies can be done using patient-derived tumor models.

GROWTH FACTORS (2023)

Article Oncology

Small extracellular vesicles promote invadopodia activity in glioblastoma cells in a therapy-dependent manner

Clarissa A. Whitehead, Haoyun Fang, Huaqi Su, Andrew P. Morokoff, Andrew H. Kaye, Eric Hanssen, Cameron J. Nowell, Katharine J. Drummond, David W. Greening, Laura J. Vella, Theo Mantamadiotis, Stanley S. Stylli

Summary: In this study, it was found that glioblastoma cells promote invadopodia activity by secreting small extracellular vesicles (sEVs) containing matrix metalloproteinase MMP-2. Additionally, the invasiveness of cells and sEV secretion were increased after radiotherapy/temozolomide treatment. These findings reveal a relationship between sEVs and invadopodia, providing important insights into the functional capacity of sEVs in promoting glioblastoma cell invasion.

CELLULAR ONCOLOGY (2023)

Article Developmental Biology

γH2AX in mouse embryonic stem cells: Distribution during differentiation and following γ-irradiation

Tom C. Karagiannis, Christian Orlowski, Katherine Ververis, Eleni Pitsillou, Gulcan Sarila, Samuel T. Keating, Laura J. Foong, Stefanie Fabris, Christina Ngo-Nguyen, Neha Malik, Jun Okabe, Andrew Hung, Theo Mantamadiotis, Assam El-Osta

Summary: This study investigates the role of phosphorylated histone H2AX (gamma H2AX) as a marker of DNA double-strand breaks (DSBs) and its implication in stem cell differentiation. The research establishes a mouse embryonic stem cell (mESC) differentiation model and examines the dynamics of gamma H2AX foci during the process. The findings reveal that gamma H2AX serves as a versatile marker of DSBs and may have a role as a biomarker in stem cell differentiation.

CELLS & DEVELOPMENT (2024)

No Data Available